cryptocurrencies transactions Top People searches

Liao Min held video talks with the heads of sovereign credit rating teams of international credit rating companies. Recently, Vice Minister of Finance Liao Min held video talks with Mary Duron, global head of Moody's Sovereignty and Local Government Risk Department, and Roberto Xifeng-Arevalo, global head of Standard & Poor's Sovereignty Rating Team, respectively, to introduce the latest incremental policies of the China government, and exchanged views with each other on issues such as government debt management, fiscal sustainability, fiscal policy supporting the high-quality development of the real economy, and fiscal and taxation system reform. Both Moody's and Standard & Poor's said that the introduction of the Ministry of Finance was comprehensive and frank, which was very helpful for them to deepen their understanding of the macro policies of the China government, and they looked forward to more exchanges between the two sides. (Ministry of Finance)Puli Pharmaceutical Co., Ltd.: It won the bid for the tenth batch of national centralized drug procurement. According to Puli Pharmaceutical, on December 12, Puli Pharmaceutical's meglumine gadolinium tetate injection (trade name: Puli Yingxian) and Posaconazole injection (trade name: Puli Posa) both won the bid for the tenth batch of national centralized drug procurement.Citigroup: Raise the target price of Autozone from $3,500 to $3,900, and maintain the "buy" rating.

Puli Pharmaceutical Co., Ltd.: It won the bid for the tenth batch of national centralized drug procurement. According to Puli Pharmaceutical, on December 12, Puli Pharmaceutical's meglumine gadolinium tetate injection (trade name: Puli Yingxian) and Posaconazole injection (trade name: Puli Posa) both won the bid for the tenth batch of national centralized drug procurement.Comments on Hong Kong stocks: Hang Seng Index fell by 2.09%, Hang Seng Technology Index fell by 2.63%, Hong Kong stocks closed, Hang Seng Index fell by 2.09% and Hang Seng Technology Index fell by 2.63%. Domestic insurance stocks and domestic housing stocks were among the top losers, with Sunac China falling more than 8%, and Xpeng Motors, China Pacific Insurance and Zijin Mining falling more than 5%.AI glasses ushered in the limelight, and Google reached a cooperation with domestic manufacturers. According to the news, on December 13, at the Android XR conference, Google reached a strategic cooperation with domestic consumer-grade AR glasses manufacturer XREAL to jointly build the Android XR ecosystem. According to media reports, OPPO, vivo, Huawei, Tencent and ByteDance are all evaluating the AI glasses project. In addition, a number of listed companies said on the investor question and answer platform that they have corresponding technology or product reserves in AI glasses. Huaxin Securities Research Report pointed out that AI glasses have become a new outlet in the smart wear market, or lead the next generation of terminal revolution. AI glasses not only have the effect of virtual vision enhancement, but also realize real-time analysis of user behavior and environment by integrating artificial intelligence algorithms, providing more accurate and personalized services. AI glasses also improve comfort and prolong wearing time in design and portability. At the same time, it provides a more natural and convenient interactive experience innovation through various sensing technologies. With the gradual reduction of costs, AI glasses are expected to be further widely used. According to the report of Wellsenn XR, it is estimated that after 2030, the AI+AR smart glasses industry will enter a period of rapid development; By 2035, AI+AR smart glasses will eventually replace traditional smart glasses, and the global sales of AI+AR smart glasses will reach 1.4 billion units, which is equivalent to the size of smart phones and will become the next generation general computing platform and terminal. (Securities Times)

Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.The head of the region said that the Russian attack on the key infrastructure in the Ivano-Frankov region was the biggest attack on the region so far.Report: By 2035, the demand for hydrogen in the global power industry may increase fourfold. According to analysis, the demand for clean hydrogen in the global power industry will reach 4 million tons by 2035. This is five times the scale of 800,000 tons of clean hydrogen agreements signed by the power industry at present. The power industry is increasingly interested in hydrogen, which is good news for hydrogen producers who are competing to find an off-buyer. However, from the climate point of view, the prospect is not so optimistic, because most global reserve projects plan to burn hydrogen and natural gas together.